SCHEMBL3496512

SCHEMBL3496512

CN1C(C)(C)CC(Nc2nc(Nc3cc(Cl)cc(Cl)c3)ncc2F)CC1(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 2/20 0.59
TYRO3 Q06418 13/20 0.48
SYK P43405 1/20 0.46
SELP P16109 7/20 0.44
EGFR P00533 4/20 0.42
BTK Q06187 4/20 0.42
CHEK1 O14757 3/20 0.42
IKBKB O14920 3/20 0.42
AURKA O14965 3/20 0.42
MAP4K4 O95819 3/20 0.42
PAK4 O96013 3/20 0.42
CHEK2 O96017 3/20 0.42
ABL1 P00519 3/20 0.42
INSR P06213 3/20 0.42
LCK P06239 3/20 0.42
FGFR1 P11362 3/20 0.42
CSNK2A2 P19784 3/20 0.42
CCNA2 P20248 3/20 0.42
CDK2 P24941 3/20 0.42
MAPK1 P28482 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3495479 0.93 PRKCQ (0.53) PRKCQTYRO3SYKSELPEGFR
SCHEMBL3495009 0.89 PRKCQ (0.61) PRKCQTYRO3SYKEGFRBTK
SCHEMBL3493194 0.89 PRKCQ (0.61) PRKCQSYKEGFRBTKAURKA
SCHEMBL3496315 0.89 PRKCQ (0.56) PRKCQSYKEGFRMAPK1AXL
SCHEMBL3497767 0.88 PRKCQ (0.62) PRKCQSYKEGFRBTKAURKA
SCHEMBL3495534 0.87 PRKCQ (0.47) PRKCQTYRO3SYKSELPEGFR
SCHEMBL3497300 0.87 PRKCQ (0.59) PRKCQSYKEGFRBTKAURKA
SCHEMBL3495899 0.87 PRKCQ (0.59) PRKCQSYKEGFRBTKCHEK1
SCHEMBL1742745 0.86 PRKCQ (0.61) PRKCQTYRO3SYKSELPAXL
SCHEMBL3495845 0.86 PRKCQ (0.56) PRKCQSYKEGFRBTKAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US claimed
EP-2183225-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2010-05-12 EP claimed
WO-2009012421-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2009-01-22 WO claimed
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed
EP-2183225-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2010-05-12 EP disclosed
WO-2009012421-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ PRKCQ 3/4885TYRO3 852/4885SYK 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.